Benign course in multiple sclerosis: a review
暂无分享,去创建一个
[1] S. Reingold,et al. Defining the clinical course of multiple sclerosis , 1996, Neurology.
[2] E. Norrby,et al. Genetic basis of multiple sclerosis: HLA antigens, disease progression, and oligoclonal IgG in CSF , 1979, Acta neurologica Scandinavica.
[3] A. Thompson,et al. Patterns of disease activity in multiple sclerosis: clinical and magnetic resonance imaging study. , 1990, BMJ.
[4] A. Prange,et al. Course and prognosis of chronic progressive multiple sclerosis: Results of an epidemiological study , 1988, Acta neurologica Scandinavica.
[5] W. Mcdonald,et al. The longstanding MS lesion. A quantitative MRI and electron microscopic study. , 1991, Brain : a journal of neurology.
[6] C. Marsden,et al. Differentiation of multiple system atrophy from idiopathic Parkinson's disease using proton magnetic resonance spectroscopy , 1995, Annals of neurology.
[7] G. Vega,et al. Apolipoproteins in human cerebrospinal fluid. , 1979, Proceedings of the National Academy of Sciences of the United States of America.
[8] S. Poser,et al. Age at onset, initial symptomatology and the course of multiple sclerosis , 1982, Acta neurologica Scandinavica.
[9] H. Carton,et al. Clinical parameters and intrathecal IgG synthesis as prognostic features in multiple sclerosis. Part I , 2004, Journal of Neurology.
[10] S H Snyder,et al. A novel neuronal messenger molecule in brain: The free radical, nitric oxide , 1992, Annals of neurology.
[11] D. Middleton,et al. A study of the HLA-DR region in clinical subgroups of multiple sclerosis and its influence on prognosis , 1999, Journal of the Neurological Sciences.
[12] P. Klivényi,et al. The Prevalence of Multiple Sclerosis, Distribution of Clinical Forms of the Disease and Functional Status of Patients in Csongrád County, Hungary , 2001, European Neurology.
[13] Anders Odén,et al. Prediction of outcome in multiple sclerosis based on multivariate models , 1994, Journal of Neurology.
[14] A. Ghezzi,et al. The benign form of multiple sclerosis , 1984 .
[15] M. Amato,et al. A prospective study on the prognosis of multiple sclerosis , 2000, Neurological Sciences.
[16] Massimo Filippi,et al. A spinal cord MRI study of benign and secondary progressive multiple sclerosis , 2004, Journal of Neurology.
[17] Sandro Sorbi,et al. Benign multiple sclerosis , 2006, Journal of Neurology.
[18] J. Kurtzke,et al. Survival in multiple sclerosis. , 1989, Journal of clinical epidemiology.
[19] R. Muller. Course and prognosis of disseminated sclerosis in relation to age of onset. , 1951, A.M.A. archives of neurology and psychiatry.
[20] A. Thompson,et al. A clinical and laboratory study of benign multiple sclerosis. , 1986, The Quarterly journal of medicine.
[21] P. Christiansen,et al. Early Time Course of JV-Acetylaspartate , Creatine and Phosphocreatine , and Compounds Containing Choline in the Brain After Acute Stroke , 2005 .
[22] S. Croul,et al. Oxidative damage to mitochondrial DNA and activity of mitochondrial enzymes in chronic active lesions of multiple sclerosis , 2000, Journal of the Neurological Sciences.
[23] N. Wilczak,et al. Beta 2-adrenoceptor involvement in inflammatory demyelination and axonal degeneration in multiple sclerosis. , 2004, Trends in pharmacological sciences.
[24] L. Steinman. A few autoreactive cells in an autoimmune infiltrate control a vast population of nonspecific cells: a tale of smart bombs and the infantry. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[25] F. Muntoni,et al. Multiple sclerosis in Sardinia is associated and in linkage disequilibrium with HLA-DR3 and -DR4 alleles. , 1997, American journal of human genetics.
[26] B. Weinshenker,et al. Identifying disease modifying genes in multiple sclerosis , 2002, Journal of Neuroimmunology.
[27] R. Forbes,et al. An epidemiologic study of multiple sclerosis in Northern Ireland. , 1999, Neurology.
[28] P. Pocklington,et al. Course of multiple sclerosis. First results of a prospective study carried out of 102 MS patients from 1976-1980. , 1982, Acta neurologica Scandinavica.
[29] O. Kantarci,et al. Survival and predictors of disability in Turkish MS patients , 1998, Neurology.
[30] J. Baskerville,et al. The natural history of multiple sclerosis: a geographically based study. 5. The clinical features and natural history of primary progressive multiple sclerosis. , 1999, Brain : a journal of neurology.
[31] A. Thompson,et al. Serial gadolinium‐enhanced MRI in relapsing/remitting multiple sclerosis of varying disease duration , 1992, Neurology.
[32] K. Spitzer,et al. Prognostic relevance of initial clinical and paraclinical parameters for the course of multiple sclerosis , 1988, Journal of Neuroimmunology.
[33] Kenneth J. Smith,et al. Electrically active axons degenerate when exposed to nitric oxide , 2001, Annals of neurology.
[34] Y. Lapierre,et al. Clinical Sub-Groups of Multiple Sclerosis in Relation to HLA: DR Alleles as Possible Markers of Disease Progression , 1985, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.
[35] A. Goris,et al. High-resolution analysis of IL-6 minisatellite polymorphism in Sardinian multiple sclerosis: effect on course and onset of disease , 2000, Genes and Immunity.
[36] C. Pozzilli,et al. Prospective study of multiple sclerosis with early onset , 2002, Multiple sclerosis.
[37] T. Riise,et al. Prognostic factors for life expectancy in multiple sclerosis analysed by Cox-models. , 1988, Journal of clinical epidemiology.
[38] William H. Oldendorf,et al. N-Acetyl-L-Aspartic acid: A literature review of a compound prominent in 1H-NMR spectroscopic studies of brain , 1989, Neuroscience & Biobehavioral Reviews.
[39] A. Hirano,et al. Asymptomatic Demyelinated Plaque , 1974 .
[40] R. Herndon,et al. Multiple sclerosis. The spectrum of severity. , 1983, Archives of neurology.
[41] K. Lauer,et al. Prognostic criteria in an epidemiological group of patients with multiple sclerosis: an exploratory study , 1992, Journal of Neurology.
[42] K. Lauer,et al. Epidemiological investigations into multiple sclerosis in Southern Hesse. V. Course and prognosis , 1987, Acta neurologica Scandinavica.
[43] P. Livrea,et al. Course and prognosis in early-onset MS , 2002, Neurology.
[44] J. Haines,et al. HLA-DR2 dose effect on susceptibility to multiple sclerosis and influence on disease course. , 2003, American journal of human genetics.
[45] G. Serio,et al. Multivariate analysis of predictive factors of multiple sclerosis course with a validated method to assess clinical events. , 1995, Journal of neurology, neurosurgery, and psychiatry.
[46] T. Olsen,et al. Early Time Course of N‐Acetylaspartate, Creatine and Phosphocreatine, and Compounds Containing Choline in the Brain After Acute Stroke: A Proton Magnetic Resonance Spectroscopy Study , 1992, Stroke.
[47] D. Mcalpine. The benign form of multiple sclerosis. A study based on 241 cases seen within three years of onset and followed up until the tenth year or more of the disease. , 1961, Brain : a journal of neurology.
[48] K. Lauer,et al. Early prognostic factors for disability in multiple sclerosis, a European multicenter study , 1992, Acta neurologica Scandinavica.
[49] W. I. McDonald,et al. Heterogeneity of blood‐brain barrier changes in multiple sclerosis , 1990, Neurology.
[50] O. Andersen,et al. Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up. , 1993, Brain : a journal of neurology.
[51] K. Smith,et al. Nitric oxide donors reversibly block axonal conduction: demyelinated axons are especially susceptible. , 1997, Brain : a journal of neurology.
[52] V. Clark,et al. Onset symptoms as predictors of mortality and disability in multiple sclerosis , 1984, Acta neurologica Scandinavica.
[53] V. Clark,et al. Factors associated with a malignant or benign course of multiple sclerosis. , 1982, JAMA.
[54] G. Barker,et al. Correlation of magnetization transfer ration with clinical disability in multiple sclerosis , 1994, Annals of neurology.
[55] T Locatelli,et al. Brain magnetic resonance imaging and multimodal evoked potentials in benign and secondary progressive multiple sclerosis. , 1995, Journal of neurology, neurosurgery, and psychiatry.
[56] David E. Anderson,et al. Molecular pathogenesis of multiple sclerosis , 1999, Journal of Neuroimmunology.
[57] T. L. Bennett,et al. In Search of a Conceptualization of Multiple Sclerosis: A Historical Perspective , 2003, Neuropsychology Review.
[58] K. Gharagozli,et al. Multiple sclerosis: report on 200 cases from Iran , 2003, Multiple sclerosis.
[59] R. P. Mackay,et al. Forms of benign multiple sclerosis. Report of two "clinically silent" cases discovered at autopsy. , 1967, Archives of neurology.
[60] E. Waubant,et al. Multiple sclerosis that is progressive from the time of onset: clinical characteristics and progression of disability. , 1999, Archives of neurology.
[61] V Cosi,et al. Multiple sclerosis: disability and mortality in a cohort of clinically diagnosed patients. , 1989, Neuroepidemiology.
[62] T. Pekmezović,et al. Survival of Multiple Sclerosis Patients in the Belgrade Population , 2002, Neuroepidemiology.
[63] P. Cabre,et al. MS and neuromyelitis optica in Martinique (French West Indies) , 2001, Neurology.
[64] M. Mendez,et al. Malignant monophasic multiple sclerosis or “Marburg's disease" , 1988, Neurology.
[65] J. Birley,et al. A CLINICAL AND EXPERIMENTAL CONTRIBUTION TO THE PATHOGENESIS OF DISSEMINATED SCLEROSIS , 1921 .
[66] J. G. Phadke. Clinical aspects of multiple sclerosis in north-east Scotland with particular reference to its course and prognosis. , 1990, Brain : a journal of neurology.
[67] G V McDonnell,et al. Benign multiple sclerosis? Clinical course, long term follow up, and assessment of prognostic factors , 1999, Journal of neurology, neurosurgery, and psychiatry.
[68] M. Hutchinson. Disability due to multiple sclerosis: a community-based study on an Irish county. , 1986, Irish medical journal.
[69] J. G. Phadke. Survival pattern and cause of death in patients with multiple sclerosis: results from an epidemiological survey in north east Scotland. , 1987, Journal of neurology, neurosurgery, and psychiatry.
[70] G. Aimard,et al. Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients. , 1980, Brain : a journal of neurology.
[71] K. Lauer,et al. Prognostic indicators in multiple sclerosis , 1986, Acta neurologica Scandinavica.
[72] D. Goodin. Survey of multiple sclerosis in Northern California , 1999 .
[73] N. Maurits,et al. Early prediction of a benign course of multiple sclerosis on clinical grounds: a systematic review , 2001, Multiple sclerosis.
[74] J. Baskerville,et al. The natural history of multiple sclerosis: a geographically based study. 3. Multivariate analysis of predictive factors and models of outcome. , 1991, Brain : a journal of neurology.
[75] Wolfgang Brück,et al. Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time. , 2002, Brain : a journal of neurology.
[76] C. Buttinelli,et al. Evolution and severity markers in 233 MS patients. , 1987, Rivista di neurologia.
[77] M. Hakama,et al. Survival of multiple sclerosis in Finland between 1964 and 1993 , 2002, Multiple sclerosis.
[78] Pierre Marie's. Lectures on Diseases of the Spinal Cord , 1895, Glasgow Medical Journal.
[79] W. Firnhaber,et al. PROGNOSTIC CRITERIA IN MULTIPLE SCLEROSIS , 1965, Annals of the New York Academy of Sciences.
[80] C. Wolfson,et al. A Markov model of the natural history of multiple sclerosis. , 1985, Neuroepidemiology.
[81] D. Mcalpine. The Benign form of Multiple Sclerosis: Results of a Long-term Study , 1964, British medical journal.
[82] M. Alter,et al. CLINICAL FACTORS ASSOCIATED WITH INCREASED DISABILITY IN MULTIPLE SCLEROSIS , 1970, Acta neurologica Scandinavica.
[83] A Benazzouz,et al. Lysolecithin-induced demyelination in primates: preliminary in vivo study with MR and magnetization transfer. , 1995, AJNR. American journal of neuroradiology.
[84] W. Brück,et al. Acute axonal injury in multiple sclerosis. Correlation with demyelination and inflammation. , 2000, Brain : a journal of neurology.
[85] John Noseworthy,et al. Clinical implications of benign multiple sclerosis: A 20‐year population‐based follow‐up study , 2004, Annals of neurology.
[86] Alireza Minagar,et al. Blood-brain barrier disruption in multiple sclerosis , 2003, Multiple sclerosis.
[87] P. Adeleine,et al. Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. , 2003, Brain : a journal of neurology.
[88] T. Riise,et al. Prognostic factors for survival in multiple sclerosis: a longitudinal, population based study in Møre and Romsdal, Norway. , 1995, Journal of neurology, neurosurgery, and psychiatry.
[89] B. Bramwell. Clinical Studies. XII.—The Prognosis in Disseminated Sclerosis; Duration in Two Hundred Cases of Disseminated Sclerosis , 1917, Edinburgh Medical Journal.
[90] P. Rudge. The value of natural history studies of multiple sclerosis. , 1999, Brain : a journal of neurology.
[91] A. Svejgaard,et al. HL-A antigens and multiple sclerosis. , 1972, Lancet.
[92] P. Gallo,et al. The HLA-DR13 haplotype is associated with “benign” multiple sclerosis in northeast Italy , 2001, Neurology.
[93] E. A. Velde,et al. Presenting signs and symptoms in multiple sclerosis , 1986, Acta neurologica Scandinavica.
[94] D. Turnbull,et al. Mitochondrial dysfunction plays a key role in progressive axonal loss in Multiple Sclerosis. , 2005, Medical hypotheses.
[95] R. Fossdal,et al. The natural history of untreated multiple sclerosis in Iceland. A total population-based 50 year prospective study , 2002, Clinical Neurology and Neurosurgery.
[96] T. Pekmezović,et al. Prognostic factors for survival in multiple sclerosis , 1999, Multiple sclerosis.
[97] Gianfranco Siracusa,et al. A prospective study on the natural history of multiple sclerosis: clues to the conduct and interpretation of clinical trials , 1999, Journal of the Neurological Sciences.
[98] A. D. Roses,et al. Association of apolipoprotein E allele €4 with late-onset familial and sporadic Alzheimer’s disease , 2006 .
[99] J. Valk,et al. 1H and 31P magnetic resonance spectroscopy of the brain in degenerative cerebral disorders , 1992, Annals of neurology.
[100] T. Richards. Proton MR spectroscopy in multiple sclerosis: value in establishing diagnosis, monitoring progression, and evaluating therapy. , 1991, AJR. American journal of roentgenology.
[101] P. Pocklington,et al. Course of multiple sclerosis , 1982 .
[102] G. Barker,et al. 1H magnetic resonance spectroscopy of chronic cerebral white matter lesions and normal appearing white matter in multiple sclerosis , 1997, Journal of neurology, neurosurgery, and psychiatry.
[103] G. Beebe,et al. Studies on the natural history of multiple sclerosis--8. Early prognostic features of the later course of the illness. , 1977, Journal of chronic diseases.
[104] M. Guérin,et al. Neurodegenerative disorders: the role of peroxynitrite , 1999, Brain Research Reviews.
[105] D. Li,et al. Benign versus chronic progressive multiple sclerosis: Magnetic resonance imaging features , 1989, Annals of neurology.
[106] J. Kurtzke. Rating neurologic impairment in multiple sclerosis , 1983, Neurology.
[107] N. Evangelou,et al. Association of the APOE ε4 allele with disease activity in multiple sclerosis , 1999, Journal of neurology, neurosurgery, and psychiatry.
[108] D. Paty,et al. A population-based study of multiple sclerosis in twins. , 1986, The New England journal of medicine.
[109] R. Mahley,et al. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. , 1988, Science.
[110] R. Weiner,et al. Effects of ECT on diabetes mellitus , 1984, Acta psychiatrica Scandinavica.
[111] Carlo Berzuini,et al. Predicting secondary progression in relapsing–remitting multiple sclerosis: a Bayesian analysis , 2001, Journal of the Neurological Sciences.
[112] D. Shepherd. Clinical features of multiple sclerosis in north‐east Scotland , 1979, Acta neurologica Scandinavica.
[113] M. Horsfield,et al. Benign and secondary progressive multiple sclerosis: a preliminary quantitative MRI study , 1994, Journal of Neurology.